Ticker > Company >

Alkem Laboratories share price

Alkem Laboratories Ltd.

NSE: ALKEM BSE: 539523 SECTOR: Pharmaceuticals & Drugs  159k   589   97

4,784.30
+7.50 (0.16%)
BSE: 20 Jun 04:01 PM

Price Summary

Today's High

₹ 4,814.75

Today's Low

₹ 4,741.40

52 Week High

₹ 6,440

52 Week Low

₹ 4,498.90

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

57,203.48 Cr.

Enterprise Value

57,094.86 Cr.

No. of Shares

11.96 Cr.

P/E

27.37

P/B

4.64

Face Value

₹ 2

Div. Yield

0.94 %

Book Value (TTM)

₹  1,030.56

CASH

1,065.85 Cr.

DEBT

957.23 Cr.

Promoter Holding

55.13 %

EPS (TTM)

₹  174.78

Sales Growth

7.66%

ROE

17.56 %

ROCE

17.86%

Profit Growth

54.01 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Alkem Laboratories Ltd.

CLAVAM TAXIM Livoerb Pregakem PLAYGARD CONDOMS Omee Almox Alkof Aldigesic Lycolyfe Ketokem Pamagin Orogard Enzoflam Gemcal Ondem Pan Pan-D Pipzo Sumo Taxim-O Traxol Xone Zaxter Zocef Merosure Swich

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year7.66%
3 Year10.53%
5 Year11.27%

Profit Growth

1 Year54.01%
3 Year1.21%
5 Year16.91%

ROE%

1 Year17.56%
3 Year16.31%
5 Year18.94%

ROCE %

1 Year17.86%
3 Year16.33%
5 Year18.58%

Debt/Equity

0.09

Price to Cash Flow

33.92

Interest Cover Ratio

23.96

CFO/PAT (5 Yr. Avg.)

0.87

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 55.13 0.00
Dec 2024 55.66 0.00
Sep 2024 55.66 0.00
Jun 2024 56.38 0.00
Mar 2024 56.74 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 23.96.
  • Company’s PEG ratio is 0.51.
  • The company has an efficient Cash Conversion Cycle of -21.98 days.
  • Company has a healthy liquidity position with current ratio of 2.59.
  • The company has a high promoter holding of 55.13%.

 Limitations

  • The company has shown a poor profit growth of 1.21% for the Past 3 years.
  • The company has shown a poor revenue growth of 10.53% for the Past 3 years.
  • Tax rate is low at 7.12.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 1,868.33 2,500.10 2,871.97 2,286.83 2,044.94
Total Expenditure 1,559.70 1,879.47 2,144.33 1,629 1,748.15
Operating Profit 308.63 620.63 727.64 657.83 296.79
Other Income 83.79 106.10 120.19 169.18 111.59
Interest 20.25 21.44 17.57 21 16.91
Depreciation 67.80 64.35 62.59 67.61 91.64
Exceptional Items -12.52 0 0 0 0
Profit Before Tax 291.85 640.94 767.67 738.40 299.83
Tax 30.08 57.69 70.09 62.17 73.95
Profit After Tax 261.77 583.25 697.58 676.23 225.88
Adjusted EPS (Rs) 21.90 48.79 58.35 56.56 18.89

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 6,677.08 7,219.68 8,829.81 9,054.55 9,747.72
Total Expenditure 5,209.43 5,270.75 7,019.45 7,677.60 7,782.59
Operating Profit 1,467.65 1,948.93 1,810.36 1,376.95 1,965.13
Other Income 95.98 190.01 199.89 266.29 305.99
Interest 38.71 42.93 37.90 86.40 81.91
Depreciation 186.84 198.93 218.98 229.85 244.35
Exceptional Items 0 -12.78 0 0 -63.83
Profit Before Tax 1,338.08 1,884.30 1,753.37 1,326.99 1,881.03
Tax 73.66 199.22 212.12 192.52 133.88
Net Profit 1,264.42 1,685.08 1,541.25 1,134.47 1,747.15
Adjusted EPS (Rs.) 105.77 140.95 128.92 94.90 146.14

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 23.91 23.91 23.91 23.91 23.91
Total Reserves 6,256.53 7,601.84 8,719.75 9,325.94 10,530.70
Borrowings 6.32 0 0 0 0
Other N/C liabilities -579.85 -717.39 -746.99 -748.38 -909.87
Current liabilities 2,579.76 2,909.94 4,123.76 3,044.83 3,106.40
Total Liabilities 8,286.67 9,818.30 12,120.43 11,646.30 12,751.14
Assets
Net Block 1,836.76 1,758.36 1,882.07 1,825.09 1,782.24
Capital WIP 313.66 323.26 232.45 185.10 49.93
Intangible WIP 0 0 0 43.65 40.85
Investments 1,794.52 1,990.21 2,393.45 2,692.96 2,685.22
Loans & Advances 100.11 102.02 133.05 112.92 138.39
Other N/C Assets 28.19 18.46 620.53 14.37 14.43
Current Assets 4,213.43 5,625.99 6,858.88 6,772.21 8,040.08
Total Assets 8,286.67 9,818.30 12,120.43 11,646.30 12,751.14
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 1,338.08 1,884.30 1,753.37 1,326.99 1,881.03
Adjustment 141.24 123.34 107.99 128.89 211.74
Changes in Assets & Liabilities -563.60 -361.86 -227.17 205.70 -53.38
Tax Paid -233.94 -321.30 -334.85 -224.16 -352.83
Operating Cash Flow 681.78 1,324.48 1,299.34 1,437.42 1,686.56
Investing Cash Flow -995.17 -1,120.99 -1,669.33 197.04 -865.60
Financing Cash Flow 172.64 -208.96 436.59 -1,711.27 -959.04
Net Cash Flow -140.75 -5.47 66.60 -76.81 -138.08

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 56.74 56.38 55.66 55.66 55.13
aniruddha singh & (please... - - - 1.01 1.01
archana singh - - - 2.00 2.00
basudeo narain singh 7.27 7.27 7.27 7.27 7.27
divya singh & (please re... - - - 1.01 1.01
inderjit kaur arora # (pl... - - - 0.01 0.01
jayanti sinha 2.46 2.46 2.46 2.46 2.46
madhurima singh& (please... - - - 4.79 6.18
madhurima singh@ (please ... 2.59 2.59 2.59 2.59 2.59
manju singh # (please re... - - - 0.08 0.08
meghna singh - - - 1.01 1.01
mritunjay kumar singh 6.42 6.42 6.42 6.42 6.42
raj kumar singh 0.45 0.45 0.45 0.45 0.45
sadhika raj 0.46 0.46 0.46 0.46 0.46
sakshi sinha 0.46 0.46 0.46 0.46 0.46
sarandhar singh # (please... - - - 0.07 0.07
sarandhar singh* (please ... 20.66 20.66 19.95 19.95 19.42
satish kumar singh # (ple... - - - 0.06 0.06
satyam sinha 0.46 0.46 0.46 0.46 0.46
seema singh - - - 2.16 2.16
shikhar raj 0.46 0.46 0.46 0.46 0.46
shrey shree anant singh 1.00 1.00 1.00 1.00 1.00
srinivas singh # (please ... - - - 0.09 0.09
madhurima singh $ (please... - - - 1.39 -
aniruddha singh& (please ... 1.01 1.01 1.01 - -
archana singh 2.00 2.00 2.00 - -
divya singh& (please refe... 1.01 1.01 1.01 - -
inderjit kaur arora# (ple... 0.01 0.01 0.01 - -
madhurima singh$ (please ... 5.39 5.39 5.39 - -
madhurima singh& (please ... 0.79 0.79 0.79 - -
manju singh# (please refe... 0.08 0.08 0.08 - -
meghna singh 1.01 1.01 1.01 - -
sarandhar singh# (please ... 0.07 0.07 0.07 - -
satish kumar singh# (plea... 0.06 0.06 0.06 - -
seema singh 2.46 2.16 2.16 - -
srinivas singh# (please r... 0.09 0.09 0.09 - -
sarvesh singh# (please re... 0.07 - - - -
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 43.26 43.62 44.34 44.34 44.87
alok kumar - - - 2.31 2.31
ashok kumar 2.26 2.26 2.25 2.25 2.25
deepak kumar singh 2.16 2.15 2.12 2.09 2.08
dsp midcap fund 2.53 2.33 1.73 1.66 1.56
government pension fund g... 1.06 1.07 1.10 1.08 1.09
hdfc life insurance compa... 1.40 1.45 1.36 1.37 1.37
icici prudential multi-as... - - - 3.65 4.11
kishor kumar singh - - - 2.82 2.82
llp 0.01 0.01 0.01 0.02 0.01
nippon life india trustee... 1.56 1.52 1.60 1.26 1.36
rajeev ranjan 2.08 1.24 1.24 1.24 1.24
rajesh kumar 2.25 1.41 1.41 1.41 1.41
sbi large & midcap fund - - - 2.16 2.98
alok kumar 2.31 2.31 2.31 - -
icici prudential large & ... - - 3.45 - -
kishor kumar singh 2.86 2.84 2.82 - -
kotak emerging equity sch... - 1.06 1.05 - -
sbi contra fund - 1.59 1.84 - -
icici prudential india op... - 4.22 - - -
icici prudential elss tax... 2.24 - - - -
nawal kishore singh 1.01 - - - -

Annual Reports

Title Link
Annual Report 2024
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
Credit FITCH
Credit CRISIL
TYPE AGENCY Link
Research BOB Capital Market
Research BOB Capital Market
Research BP Wealth
Research BP Wealth
Research BOB Capital Market
Research BOB Capital Market
Research HDFC Securities
Research BOB Capital Market
Research Edelweiss
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research HDFC Securities
Research HDFC Securities
Research Motilal Oswal
Research HDFC Securities
Research BOB Capital Markets Ltd.
Research Reliance Securities

Concalls & Presentations

TYPE QUARTER Link
Concall Q4FY24
Concall Q4FY22
Concall Q3FY24
Concall Q3FY22
Concall Q3FY21
Concall Q3 FY20
Concall Q2FY22
Concall Q2FY21
Concall Q1FY25
Concall Q1FY23
Concall Q1FY21
Concall Q1FY20
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY21
Presentation Q3FY24
Presentation Q3FY22
Presentation Q3FY21
Presentation Q3 FY20
Presentation Q2FY25
Presentation Q2FY23
Presentation Q2FY22
Presentation Q2FY21
Presentation Q1FY25
Presentation Q1FY25
Presentation Q1FY25
Presentation Q1FY22
Presentation Q1FY21
Presentation Q1FY20

Company News

Alkem Laboratories Stock Price Analysis and Quick Research Report. Is Alkem Laboratories an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Alkem Laboratories and its performance over the period of time. Alkem Laboratories stock price today is Rs 4,773.50.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Alkem Laboratories cash from the operating activity was Rs 1,686.56 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Alkem Laboratories has a Debt to Equity ratio of 0.09 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Alkem Laboratories , the EPS growth was 54.01 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Alkem Laboratories has OPM of 20.16 % which is a good sign for profitability.
     
  • ROE: Alkem Laboratories have a average ROE of 17.56 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Alkem Laboratories is Rs 4,773.50. One can use valuation calculators of ticker to know if Alkem Laboratories share price is undervalued or overvalued.
Last Updated on:
Brief about Alkem Laboratories
X